Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 8/20 | 0.49 |
| ▸ | CCNK | O75909 | 8/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.49 |
| ▸ | CDK2 | P24941 | 8/20 | 0.49 |
| ▸ | CDK9 | P50750 | 8/20 | 0.49 |
| ▸ | CDK12 | Q9NYV4 | 8/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 4/20 | 0.39 |
| ▸ | CCNH | P51946 | 4/20 | 0.39 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25029249 | 0.95 | GSK3B (0.45) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL29362063 | 0.95 | GSK3B (0.45) | CCNT1CCNKCCNE1CDK2CDK9 | |
| Trifluoroacetic Acid SCHEMBL29361361 | 0.92 | CCNT1 (0.48) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL29364439 | 0.91 | GSK3B (0.48) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL25028661 | 0.91 | GSK3B (0.48) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL25027642 | 0.89 | GSK3B (0.47) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL25028677 | 0.85 | GSK3B (0.45) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL29364077 | 0.85 | GSK3B (0.45) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL25028880 | 0.84 | GSK3B (0.43) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL25027656 | 0.84 | GSK3B (0.43) | CCNT1CCNKCCNE1CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230049406-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049406-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | CCNT1 2902/4885CCNK 2842/4885CCNE1 3298/4885 |
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | CCNT1 2934/4885CCNK 2738/4885CCNE1 3371/4885 |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | CCNT1 3119/4885CCNK 3289/4885CCNE1 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.